The size of the Autoimmune Diagnostics Market in Europe was worth USD 3.78 billion in 2022 and estimated to reach USD 4.54 billion by the end of 2027, growing at a CAGR of 3.76%.
Autoimmune diseases arise once the immune system attacks one or more of the body's normal parts as if they were invaders. When the immune system fails to identify "self" it may produce immune cells or antibodies that target its own tissues, cells, and organs. Developed countries of Europe have a projected high occurrence rate of autoimmune disorders compared to other regions of the autoimmune disease diagnostics. The strike rate of autoimmune diseases is more in women compared to men. The presence of large untapped opportunities available in the developing Eastern European countries is expected to fuel the growth of the market.
High occurrence of autoimmune disorders, Supportive government policies, increasing public awareness, increased government funding aimed at improving healthcare infrastructure, the introduction of advanced technologies such as novel biomarkers and portable diagnostic equipment are the major factors driving the growth of the market.
The key restraints that inhibiting the growth of the autoimmune diagnostics market are the low prevalence of localized autoimmune disorders as compared to systemic diseases and the growing rate of diagnostics errors.
This research report is on the European Autoimmune diagnostics market has been segmented & sub-segmented into the following categories:
By Test Type:
By Disease Type:
By End User:
Companies leading the European Autoimmune disease market profiled in this report are Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli Lilly and GlaxoSmithKline Plc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org